Please assess the completion status of the following clinical trial:

Trial Title: Denosumab in Primary Hyperparathyroidism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed hypercalcemic PHPT in postmenopausal women with serum calcium \>10.2 mg/dL and \< 12.0 mg/dL (nl: 8.6-10.2)~* T-score between -1.5 and -2.5 at any site. If the T-score is \<-2.5, patients become candidates for parathyroid surgery. They will be enrolled only if they refuse the parathyroid surgery~Exclusion Criteria:~* 25-hydroxyvitamin D level \< 20 ng/ml~* Previous use of the bisphosphonate zoledronic acid (ever), alendronate or risedronate (within 12 months) or ibandronate (within 6 months)~* Current use of PTH, glucocorticoids, SERMS, estrogen (other than vaginal), calcitonin or pharmacological amounts of calcitriol Current or previous use of cinacalcet (within 6 months)~* Hyperthyroidism~* Rheumatoid arthritis or any other inflammatory joint disease~* Paget's disease of bone~* Malabsorption~* T-score \<-3.5 at any site~* Signs of symptomatic PHPT (e.g, kidney stones within the past 5 years; fragility fracture within the past 2 years)~* Physical or mental handicapping condition that precludes ability to complete the protocol and/or provide informed consent.~* Subjects on Antiviral HIV therapy or subjects with compromised immune systems~* Premenopausal women or men~* Stage 5 Chronic Kidney Disease (CKD) or anyone on dialysis~* Creatinine clearance \< 30 cc/min unless the patient is not a candidate for surgery or if the patient refuses surgery

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Denosumab - Group #1 (Type: EXPERIMENTAL): Receive active drug for year 1 and year 2 of the study
- Placebo - Group #2 (Type: PLACEBO_COMPARATOR): Receive placebo for year 1 and active drug for year 2 of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).